Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer

A private insurer is calling for CMS to issue a national non-coverage decision for proton therapy in treating prostate cancer, claiming Medicare payments will encourage rapid spread of the costly technology before there is enough clinical evidence to deem the treatment reasonable and necessary